Home
About Us
Introduction
Milestones
Management Team
Advisory Board of Clinical Experts
Vision & Mission
Strategy
Robust Pipeline
Clinical Development
Technology Platform
Collaborations
News
Press Releases
Interview
Careers
Contact Us
CN
EN
CN
|
EN
Home
About Us
Introduction
Milestones
Management Team
Advisory Board of Clinical Experts
Vision & Mission
Strategy
Robust Pipeline
Clinical Development
Technology Platform
Collaborations
News
Press Releases
Interview
Careers
Contact Us
Dr. Yong jiang Hei will present at ACCESS CHINA Biotech Forum
2022-01-03
Pre
Hot news
BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3(GPC3)
2024-04-10
>>
BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial
2024-07-08
>>
BioCity announces the first patient dosed with its first-in-class CDH3-targeting ADC BC3195 in a Phase 1 Trial
2023-07-20
>>